For more information, visit our Radiation Oncology Program
Return to Cancer Program Name Search
Title: Prospective Phase I Trial of Hypofractionated Radiation Therapy in Retroperitoneal Sarcoma
Brief Title: Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
Brief Summary: To determine the safety of moderately hypofractionated radiation in the treatment of
primary and locally recurrent RPS, based on the evaluation of acute radiation-related
toxicity profile of each participant (30-day radiation toxicity)
For info regarding 24-450
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Development of an Artificial Intelligence model to predict surgical findings at prostatectomy from preoperative data
Brief Title: Model for prostatectomy prediction
For info regarding 22-214
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Prospective multicenter observational study for validation of a pancreatic cancer risk model and assessment of the predictive value of blood biomarkers in a high-risk cohort
Brief Title: Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
Brief Summary: The purpose of this study is to test a double screening strategy for pancreatic cancer,
based on a model developed using patient medical records. Investigators would also like
to test whether adding specific blood tests, can further help identify people who have a
higher risk of pancreatic cancer than the general population, and would benefit from
imaging in order to detect cancer early.
For info regarding 21-490
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Phase IB Study of Atezolizumab and Bevacizumab with SBRT for Unresectable Hepatocellular Carcinoma
Brief Title: Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
Brief Summary: This research study is evaluating the safety and tolerability of the drugs atezolizumab
and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable
hepatocellular carcinoma.
This study involves the following interventions:
- Atezolizumab
- Bevacizumab
- Stereotactic body radiation therapy (SBRT)
For info regarding 21-286
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Development of a pancreatic cancer screening platform using clinical and biological markers
Brief Title: Development of a pancreatic cancer screening platform
For info regarding 21-010
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Prospective evaluation of patient-reported perceived pain response and comparison to international consensus guidelines in patients receiving palliative radiation for bone metastases
Brief Title: Prospective evaluation of patient-reported pain
For info regarding 20-567
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Prospective evaluation of overall and symptomatic quality of life among patients receiving radiation therapy for symptomatic leptomeningeal disease of the brain or spine
Brief Title: QOL IN LEPTOMENINGEAL DISEASE OF THE BRAIN OR SPINE
For info regarding 18-627
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Evaluation of Quality of Life Issues Among Patients Receiving SBRT for Non-Organ Soft Tissue and Bone Metastases
Brief Title: QOL ISSUES IN SOFT TISSUE + BONE METASTASES
For info regarding 18-614
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: RSSearch® Patient Registry Protocol
Brief Title: RSSEARCH PATIENT REGISTRY
For info regarding 16-098
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
Brief Title: A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
Brief Summary: CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very
accurately to a tumor. The ability of this technology to minimize radiation dose to
organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus
potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is
commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized
prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for
the treatment of clinically localized primary renal cell carcinoma.
For info regarding 12-235
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Retrospective Review of Patients Treated with CyberKnife Radiosurgery and Stereotactic Body RadioTherapy
Brief Title: Retrospective Review of CK Treatment
For info regarding 09-451
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu